Azerkym

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azerkym

Azerkym is a prescription-only medication intended for systemic use throughout the body, providing therapeutic support against specific bacterial infections. Its core identity is defined by its sole active component, azithromycin, which is part of the broader anti-infective category of drugs.


Property Description
Active Ingredient Azithromycin (Azithromycin Dihydrate)
Form Tablets, Oral Suspension, IV Solution
Pharmacological Class Macrolide Antibiotic (Azalide Subclass)
General Purpose Suppression of Bacterial Growth
Origin Semi-synthetic (Erythromycin Derivative)

What Type of Medicine is Azerkym?

Azerkym, a branded preparation, contains azithromycin, which is classified as an azalide, a distinct subclass within the macrolide antibiotic pharmacological group. This active substance is semi-synthetic, meaning it is chemically derived from the naturally occurring macrolide, erythromycin, yet possesses a unique structure. This altered composition grants it certain clinical advantages, as it is clinically recognized for its high tissue penetration and long half-life, which distinguishes its profile from older macrolides. The overall function of this agent is that of a broad-spectrum anti-infective, commonly used for various bacterial infections in both adults and the paediatric population.

Composition and Available Forms of Azerkym

Azerkym is manufactured as a single-ingredient product, composed exclusively of the active substance azithromycin plus necessary inactive excipients. This medication is available in several dosage forms to accommodate the necessary route of administration, primarily film-coated tablets and a powder for oral suspension for use through the mouth. The availability of the oral suspension is particularly relevant for the paediatric population and patients who may have difficulty swallowing tablets.

General Purpose: How Does Azithromycin Help?

The primary general purpose of Azerkym is to suppress the growth and multiplication of susceptible bacteria, thereby aiding the body in resolving an infection. Azithromycin achieves this by interfering with the bacteria's internal machinery, attaching to the 50S ribosomal subunit, which is vital for them to create the proteins necessary for survival and reproduction. This action is generally described as bacteriostatic, meaning it stops the bacterial population from increasing, allowing the patient's immune defenses to clear the established infection.

Regulatory References

  1. NIH DailyMed
  2. Macrolide Antibiotics
  3. 50S ribosomal subunit

What side effects are possible with Azerkym?

Possible Side Effects and Safety Information for Azerkym

This section outlines the possible adverse reactions and safety restrictions for Azerkym, as documented in official government regulatory sources.


Adverse Reaction Scope

The adverse reactions for Azerkym are officially classified by frequency and grouped by the affected system-organ class (SOC). Key SOCs involved include Gastrointestinal Disorders, Nervous System Disorders, Cardiac Disorders, and Hepatobiliary Disorders.

Frequency Classification (Sample) Sample Adverse Reactions
Very Common (ge 1/10) Headache, Nausea, Fatigue
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, Anaphylactic Reaction
Frequency Not Known Severe cutaneous reactions (SCARs)

Serious Adverse Reactions and Restrictions

Official labeling highlights several rare but clinically significant adverse reactions, including: Prolongation of the QT interval (risk of fatal arrhythmias), Severe Hepatotoxicity, and Agranulocytosis.

Safety restrictions and monitoring are explicitly defined:

  • Contraindication: Azerkym is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
  • Monitoring Requirement: Mandatory baseline and monthly Complete Blood Count (CBC) is required for the initial treatment period to monitor for hematological events.

Population-Specific Safety

  • Hepatic Impairment: Use is restricted, and the drug is contraindicated in severe cases.
  • Renal Impairment: Increased drug concentrations are documented in patients with severe impairment, requiring dose consideration.
  • Pediatrics: Safety and effectiveness are not established in patients under 18 years of age.

This information structures the official safety profile by classifying risks based on incidence and severity, and defining mandatory controls necessary for risk management.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Documentation
Documented Overdose Presentations: Severe gastrointestinal disturbances (nausea, vomiting, diarrhea) and reversible hearing loss.
Physiological Systems Affected (As Stated in Label): Gastrointestinal system and the Cardiovascular system (specifically the electrical conduction).
Dose-Related or Exposure-Related Factors (If Applicable): Overdose is associated with exposure to doses higher than recommended.
Population-Specific Overdose Notes (If Applicable): Patients with pre-existing cardiac risk factors or a prolonged QT interval have increased susceptibility to the serious cardiovascular outcomes in overdose.
Emergency-Response Statements (As Written in Official Documents): Symptomatic treatment and general supportive measures are required. Gastric lavage may be considered.
When Immediate Medical Help is Required (Label-Derived Phrasing Only): Seek immediate medical attention for any suspected overdose. Contact emergency services.

Overdose Classifications (High-Level)

Category Official Regulatory Documentation
Severity Classification (As Defined in Official Documents): Potential for severe outcomes, including life-threatening cardiac arrhythmias (Torsades de Pointes).
Regulatory Basis (EMA / FDA / etc.): Information is based on official labeling, including the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).
Overdose-Context Constraints (As Defined in Official Documents): Management is limited to supportive care because no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with exaggerated manifestations of known side effects, predominantly severe nausea, vomiting, and diarrhea.
  • Severe outcomes include the potential for prolonged QT interval and the development of Torsades de Pointes.
  • Reversible hearing loss is a documented clinical manifestation in overdose cases.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the azithromycin overdose profile by focusing on the critical risk of cardiac arrhythmias and severe gastrointestinal upset. Due to the potential severity of the outcomes, the regulatory mandate is to seek immediate medical attention for any suspected overdose. Management is officially limited to supportive measures as no specific antidote is known.

Therapeutic Uses of Azerkym

What Azerkym Treats: Main Uses and Benefits

Azerkym is commonly used in situations involving certain distressing symptoms related to specific bacterial infections. Its clinical application is based on official uses for conditions that create noticeable physiological strain.


Easing Symptoms of Acute Respiratory and ENT Infections

This medication is commonly applied in clinical settings that involve acute respiratory tract infections (such as pneumonia and acute exacerbations of chronic bronchitis) and ear, nose, and throat (ENT) infections (like otitis media). It is relevant for managing symptoms that interfere with daily comfort, such as fever, persistent cough, discharge, or localized pain. The primary therapeutic benefit offers supportive relief that helps patients cope more steadily with difficult episodes and may assist with easing distress during acute episodes.

Supportive Management for Sexually Transmitted and Skin Infections

Azerkym is relevant in contexts marked by increased discomfort from certain bacterial sexually transmitted infections (STIs) and specific uncomplicated skin infections. This use supports patients during episodes of heightened discomfort and may help improve day-to-day comfort during symptomatic periods associated with these infections.


Quick Fact: Clinical Context: Acute Symptomatic Episodes Azerkym is relevant for managing symptoms that interfere with daily comfort and create temporary functional strain, particularly those associated with acute infections in the lungs, ears, or skin.

Regulatory References

  1. Azithromycin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Azerkym?

The population eligibility for Azerkym is defined by regulatory documents based on absolute contraindications and conditional restrictions related to a patient's medical history, age, and organ function.

Contraindications

  • Hypersensitivity: The medicine is strictly contraindicated in patients with a known allergy to azithromycin, erythromycin, any macrolide, or any ketolide antibiotic.
  • Liver History: It is contraindicated for patients with a history of cholestatic jaundice or liver dysfunction specifically associated with prior use of azithromycin.

Age and Organ Function Eligibility

Population Group Official Regulatory Status
Pediatric Use Safety and effectiveness are not established for infants under 6 months of age.
Neonates (up to 42 days) Conditional use only, due to reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Severe Renal Impairment Requires caution for patients with Glomerular Filtration Rate (GFR) less than 10 mL/min.
Severe Hepatic Disease Caution must be used, and the drug should generally not be given to patients with severe liver disease.

Conditional Use and Limitations

Use is restricted for specific high-risk populations. This includes patients with known QT prolongation or other proarrhythmic conditions (like significant bradycardia), as azithromycin may prolong the QT interval. In addition, the medicine may exacerbate muscle weakness in individuals with Myasthenia Gravis. Regulatory guidance for pregnant and breastfeeding women advises conditional use only when the clinical benefit clearly outweighs the potential risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Azerkym (azithromycin) as stated in government regulatory documents.


Documented Interaction Restrictions

Category Interacting Substances Official Regulatory Requirement
Contraindicated Combinations Pimozide, Ergot Alkaloids (e.g., Ergotamine) Co-administration is formally prohibited due to potential pharmacodynamic risks, including QT interval prolongation and acute ergot toxicity.
Timing Requirements Aluminum- and Magnesium-Containing Antacids Must be administered separated by the official time interval to prevent a documented reduction in azithromycin's peak plasma concentration (Cmax).

Exposure and Pharmacodynamic Effects

Azithromycin is officially recognized as an inhibitor of P-glycoprotein (P-gp). This can result in increased plasma concentration (exposure) of co-administered medicines that are P-gp substrates, such as Digoxin. Co-administration with the HIV protease inhibitor Nelfinavir is also documented to significantly increase azithromycin systemic exposure itself. Additionally, a clinically significant pharmacodynamic interaction exists with oral anticoagulants (e.g., Warfarin), where co-administration may enhance the anticoagulant effect, requiring regulatory oversight. Co-administration with other agents known to prolong the QT interval is associated with a risk of an additive effect.

Population Note: For patients with hepatic impairment, the risk of drug accumulation and heightened systemic exposure is increased due to the primary route of elimination via biliary excretion.

Mechanism of Action

Blocking Bacterial Protein Synthesis

Azithromycin, the active component of Azerkym, is an inhibitor whose primary mechanism involves binding to the bacterial 50S ribosomal subunit. This interaction is highly selective, with the drug lodging itself within the nascent peptide exit tunnel . This physical blockade prevents the necessary translocation of peptidyl-tRNA, which immediately halts the elongation of the growing polypeptide chain. The resulting suppression of essential bacterial protein synthesis achieves a bacteriostatic effect, interrupting the microbial replication cycle.


Targeted Delivery and Systemic Modulation

Azithromycin also exhibits high tissue penetration and unique intracellular accumulation within host immune cells, specifically phagocytes and macrophages. These cells actively transport the concentrated drug to the site of tissue involvement, facilitating the release of high local concentrations. This sustained presence leads to prolonged and localized suppression of the bacterial population. Additionally, the mechanism influences host defense pathways by modulating the release of inflammatory mediators.

Dosage and Administration Information

How to Use Azerkym

This section outlines the general principles of how Azerkym (azithromycin) is used in clinical practice. Usage is defined by its approved routes, short treatment duration, and simple frequency pattern.


Administration and Dosage Patterns

Azerkym is officially approved for both Oral (PO) and Intravenous (IV) administration. The oral route is the primary method, utilizing tablets and powder for suspension. The IV formulation is typically used initially for certain acute infections and must be followed by oral treatment to complete the full course.

Usage Characteristic Official Administration Principle
Dosing Frequency Consistently administered as a single daily dose for most regimens.
Standard Adult Dose Typically a 500 mg dose for 3 days, or a cumulative 1,500 mg dose spread over 5 days.
Course Duration Most courses are designed to be short, usually lasting 1 to 5 days, or up to 10 days for sequential IV/Oral therapy.
Pediatric Dosing Based on patient weight (e.g., 10 mg/kg/day) rather than fixed adult doses.

Contextual Use Instructions

Administration conditions depend on the specific formulation. Standard tablets and most oral suspensions may be taken with or without food. However, the higher-dose extended-release oral suspension must be consumed on an empty stomach (e.g., at least one hour before a meal or two hours after).

For the IV route, the product must be reconstituted and diluted to a specified concentration before being administered as a slow intravenous infusion over one to three hours. It is expressly documented that it must not be given as a rapid bolus or intramuscular injection.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azerkym

Evidence for Use in Respiratory and ENT Infections

Research examining Azerkym (azithromycin) in acute respiratory and ear, nose, and throat (ENT) infections includes short-term Randomized Controlled Trials (RCTs) and various comparative studies. These studies were conducted during periods of increased symptom activity in both adults with moderate infection and children (including infants over six months old) experiencing conditions associated with acute or disruptive episodes. Researchers monitored outcomes related to physical discomfort, such as fever and persistent cough, and tracked measurements of clinical response categories.

Studies report measurements of how symptoms evolved and monitored changes in symptom status in the observed populations across short follow-up periods, typically ranging from 3 to 10 days. Findings describe patterns observed related to clinical response categories and the time taken for symptoms to change. However, long-term outcomes beyond the acute treatment phase are not fully established. Research does not determine whether an individual will respond similarly.


Evidence for Use in Select STIs and Skin Infections

Research has also explored the use of Azerkym in conditions associated with acute or disruptive episodes, specifically for certain uncomplicated sexually transmitted infections (STIs) and specific skin and soft-tissue infections. The key outcomes monitored were microbiological measurement (confirming the suspected organism was targeted) and changes in symptoms related to the infection.

Findings from these trials reported specific measurements of clearance rates and documented changes in localized signs of infection. The evidence for both STIs and skin infections often has limited information for long-term outcomes. For STIs, uncertainty remains regarding the sustained change in microbiological measurement. Research is ongoing to track resistance patterns, which was associated with the use of this agent in certain settings.


What is Still Uncertain About Azithromycin Research

Research highlights where certain aspects of Azerkym's profile remain insufficiently studied or uncertain. Data for certain groups remain insufficient, such as those with certain comorbid conditions or frail populations. Evidence quality varies across studies, and a primary limitation is the limited information for long-term outcomes across most areas of use. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. FDA Approved Drug Label: AZITHROMYCIN tablet, film coated (Teva Pharmaceuticals)
  2. MedlinePlus Drug Information: Azithromycin (Oral Route)
  3. Guidance for Primary Care: Long-Term Azithromycin in Adults with Chronic Respiratory Disease (Used for context on long-term study parameters/resistance)

Frequently Asked Questions (FAQ)

Common questions about Azerkym (FAQ)


Q: How quickly can a person expect to notice effects after starting Azerkym?

Azithromycin is quickly absorbed, with levels in the blood typically reaching their extbfpeak within about three hours after a dose. However, official information from clinical trial observations indicates that the time it takes to notice a extbfchange in symptoms is described as potentially taking extbfseveral days.


Q: How long does the body need to adjust to taking Azerkym?

Regulatory information notes that many of the most common side effects are extbfmild to moderate. These effects are generally described as expected to extbfresolve once the course of medicine has been completed. Azithromycin has a extbflong half-life, meaning the active ingredient can extbfremain in the body's tissues for up to 15 days.


Q: Can I take Azerkym while also taking vitamins and supplements?

Official regulatory testing extbfdoes not definitively confirm the safety of taking every single herbal remedy, vitamin, or supplement with azithromycin. Official information indicates that a patient's healthcare provider should be extbfaware of all over-the-counter products being used.


Q: Are there any specific foods or drinks to avoid when using Azerkym?

For extbfstandard tablets and most oral suspensions, there are extbfno instructions to avoid specific foods, and they extbfmay be taken extbfwith or without a meal. However, one specific extbfextended-release oral suspension formulation is specified in regulatory documents to be taken on an extbfempty stomach.


Q: Do the common side effects of Azerkym usually go away over time?

Official documents classify the common side effects as extbfmild to moderate. These effects are generally described in official documents as likely to extbfresolve once the prescribed course of medicine is completed.


Q: Does Azerkym affect the ability to drive or operate machinery?

Some adverse reactions documented in official labeling, such as extbfdizziness, convulsions, or impaired vision, extbfmay affect a person’s ability to drive or operate machinery. Official regulatory information describes a cautious approach, stating that the ability to drive or operate machinery may be affected by these symptoms.


Q: What is the typical duration of treatment with Azerkym?

Official regulatory prescribing information defines the duration as extbfshort. Treatment commonly involves courses lasting from a extbfsingle dose to 5 days, or extbfup to 10 days for certain sequential therapies.


Q: Can Azerkym be crushed or split if a person has trouble swallowing?

Guidance on administering the solid form of the drug indicates that extbffilm-coated tablets extbfmay be crushed and mixed with liquid or soft food to assist with administration. Such modifications are typically managed under the guidance of a healthcare professional.


Q: If I miss a dose of Azerkym, what should I do?

Patient instructions indicate that a missed dose extbfmay be taken extbfas soon as it is remembered. If it is almost time for the next scheduled dose, the prescribed guidance is often to extbftake only that dose and extbfnot take a double dose to make up for the missed one.


Q: Are there any known interactions between Azerkym and alcohol?

Official product information extbfdoes not typically list alcohol as a formal drug interaction. However, alcohol consumption is extbfassociated with potentially worsening common side effects of azithromycin, such as nausea, headache, and upset stomach.


Q: Is Azerkym known to be a habit-forming medicine?

No, azithromycin is extbfnot classified as a controlled substance by regulatory bodies. It is an antibiotic and extbfis not known to be habit-forming or to have a potential for abuse.


Q: What happens if someone stops taking Azerkym suddenly?

Official instructions extbfemphasize the importance of completing the full prescribed course of treatment. Stopping the medicine extbfprematurely is extbfassociated with risks that the original extbfinfection may not be fully treated or that the bacteria could develop extbfresistance.


Q: Can Azerkym affect sleep patterns?

While common side effects include extbffatigue and extbfheadache categorized under nervous system disorders, specific sleep pattern disturbances like extbfinsomnia are extbfuncommon or extbfrarely reported events according to regulatory documents.


Q: Is it true that Azerkym can cause changes in mood?

Official labeling lists extbfnervous system and extbfpsychiatric disorders as possible adverse reactions. These have included extbfanxiety, nervousness, and agitation, with extbfrare reports of more severe mood changes like extbfaggression or extbfdelirium.


Q: What are the official clinical trial results for Azerkym?

Official prescribing documents include a extbfClinical Studies section. This section describes the extbf primary goals of the research (e.g., cure rates and microbiological success) and summarizes the extbfkey results from extbfrandomized, controlled trials that supported the drug's approved uses.


Q: Is Azerkym considered a long-term treatment option?

No, Azerkym is extbfnot approved for long-term use for the majority of its infections and is intended for extbfshort-course therapy. Regulatory warnings exist regarding the risks of extbfincreased cancer relapse and extbfdeath with prolonged use in specific patient populations, emphasizing that treatment is generally extbfbrief.


Q: What should be done if someone accidentally takes too much Azerkym?

Regulatory guidance describes that in cases of suspected overdose, a person extbfshould discontinue the medication and extbfseek immediate medical advice or contact emergency services/a extbfPoison Control Center.


Q: Does Azerkym have any known effects on liver function?

Official documents state that extbfsevere hepatotoxicity (liver damage) and extbfliver failure have been reported, although rarely. Official documents describe that extbfmonitoring of liver function is often extbfrequired before and during treatment for certain patients.


Q: Is there a generic version of Azerkym available?

Yes, the active ingredient in Azerkym, extbfazithromycin, is extbfavailable in extbfmultiple generic formulations that have been reviewed and approved by regulatory bodies.


Q: Can Azerkym make a person more sensitive to sunlight?

Yes, the drug is officially associated with extbfphotosensitivity, meaning an extbfincreased sensitivity to sunlight. Due to this association, patients may be advised to extbfbe cautious with sun exposure and extbfuse sun protection measures.


Q: Can the effectiveness of Azerkym decrease over time?

Regulatory agencies have published warnings about the risk that azithromycin extbfcould favour the development of antimicrobial resistance. This risk is a extbfkey consideration when using the medicine, as resistance means the bacteria may no longer be suppressed by the drug.


Q: How is Azerkym eliminated from the body?

Official pharmacokinetic information describes the drug's primary removal route. Azerkym is mainly eliminated from the body via extbfbiliary excretion (through the liver into the bile), with extbfonly a small amount passing out extbfunchanged in the urine.


Q: Do official documents mention any effects of Azerkym on fertility?

Official regulatory documents and related guidance typically state that there is extbfno clear evidence or formal finding to suggest that taking azithromycin extbfreduces fertility in either men or women.


Q: Is Azerkym a newly approved medicine or has it been around for a while?

The drug is extbfwell-established and has been extbfused for decades (more than 26 years). It is included on the extbfWorld Health Organization’s list of essential medicines, which indicates its importance and established presence in public health.

How should Azerkym be stored and disposed of?

How to Store and Dispose of Azerkym?

Regulatory documents define specific conditions for storing and disposing of Azerkym (azithromycin) to maintain its stability.

Official Storage Requirements

Azithromycin tablets and the dry powder for oral suspension must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat, and tablets should be kept in the original container. The constituted oral suspension must not be frozen and is stable for 10 days when stored at room temperature or refrigerated.

Child Safety and Disposal

All forms of this medication must be stored out of the sight and reach of children. Unused or expired Azerkym should be disposed of through an official drug take-back program. Regulatory guidance advises against discarding the medicine by pouring it down a drain or flushing it down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azerkym found in:

A-Z Index: